What is Beryl Drugs Ltd (524606) share price return in the past 10 years?

Beryl Drugs Ltd share price has declined -4.4% annually (CAGR) over the past ten years.

What is the share price of Beryl Drugs Ltd (524606)?

Company share prices are keep on changing according to the market conditions. The current trading price of Beryl Drugs Ltd (524606) on 07-Jul-2026 16:59:59 at 16:59 is 22.76.

What is the P/E ratio of Beryl Drugs?

The latest standalone P/E ratio of Beryl Drugs as of 07-Jul-2026 is 24.74.

What is the P/B ratio of Beryl Drugs Ltd (524606)?

The latest standalone P/B ratio of Beryl Drugs Ltd (524606) as of 07-Jul-2026 is 1.07.

What is the 52-week high and low of Beryl Drugs Ltd (524606)?

The 52-week high of Beryl Drugs Ltd (524606) is Rs. 30.00 and the 52-week low is Rs. 15.92.

Beryl Drugs Ltd (524606)

Name: Beryl Drugs Ltd (524606)
Brand: Beryl Drugs

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524606 NSE: Pharmaceuticals & Drugs | Small Cap | Beryl Drugs Share Price

₹22.76 2.03 (9.79%)

As on 07-Jul'26 16:59

Beryl Drugs Ltd (524606)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524606 NSE: Pharmaceuticals & Drugs | Small Cap | Beryl Drugs Share Price

₹22.76 2.03 (9.79%)

As on 07-Jul'26 16:59

Key Metrics

Valuation Multiples

Market Cap

₹11 Cr.

Current Price

₹22.8

52-Week Low / High

₹16 / 30

TTM EPS

₹0.8

TTM Sales

₹18.8 Cr.

Book Value per Share

₹19.5

P/E Ratio

24.74

Higher than its 5-year historical median

Industry PE

Price to Book (P/B)

1.07

In line with its 5-year historical median

Price to Sales (P/S)

0.56

Higher than its 5-year historical median

EV/EBITDA

5.21

Lower than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

6.30%

Underperforms industry median

Return on Capital Employed (ROCE)

10.15%

Underperforms industry median

Return on Assets (ROA)

3.43%

Operating Profit Margin

4.7%

Net Profit Margin

2.74%

Gross Profit Margin

10%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-20.88%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-54.55%

Net Profit Growth (1 Year)

-24.68%

Asset Quality

Promoter Holding

27.48%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹5 Cr.

Equity

₹5.1 Cr.

Face Value

₹10

All Time Low / High

₹0.60 / 53.00

Beryl Drugs stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Beryl Drugs Ltd a good quality company?

Beryl Drugs Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Beryl Drugs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Beryl Drugs Ltd vs industry peers?

Beryl Drugs Ltd revenue CAGR is 10.53%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Beryl Drugs Ltd?

Promoters hold 27.48% of the Beryl Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Beryl Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -6.2% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	5.6%	4.5%	16.9%	10%	4.1%	6.3%	-3.8%	11.5%	11.1%	10.2%	-
Value Creation Index ⓘ	-0.6	-0.7	0.2	-0.3	-0.7	-0.6	-1.3	-0.2	-0.2	-0.3	-
Growth Parameters ⓘ
Sales ⓘ	13.1	11	15.1	13	12.8	14.1	14.6	26.9	26.7	21.2	19
Sales YoY Gr.	-	-16.2%	37.8%	-14.4%	-1.1%	9.9%	3.6%	84%	-0.5%	-20.9%	-
Adj EPS ⓘ	0.2	0.2	1.3	1.2	0.1	-0.2	-1.3	1.5	1.5	1.1	0.8
YoY Gr.	-	16.7%	528.6%	-10.6%	-92.4%	-266.7%	NA	NA	-0.7%	-24%	-
BVPS (₹) ⓘ	13.1	13.4	13.1	14.8	15	15.6	14.3	15.9	17.6	18.7	19.5
Adj Net Profit ⓘ	0.1	0.1	0.7	0.6	0.1	-0.1	-0.7	0.8	0.8	0.6	0
Cash Flow from Ops. ⓘ	-0.1	0.3	-0.1	3.4	0.2	0.3	-0.5	2.4	0.8	2.6	-
Debt/CF from Ops. ⓘ	-13.5	6.3	-14.8	1	28.3	15.1	-11.3	1.9	6.2	1.6	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.5%	10.5%	13.2%	-20.9%
Adj EPS ⓘ	22.8%	66.2%	NA	-24%
BVPSⓘ	4%	4.5%	9.3%	6.6%
Share Price	-4.4%	19.3%	9.3%	-1%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.4	1.6	10	8.4	0.6	-1	-8.6	10	9	6.3	4.4
Op. Profit Mgn % ⓘ	3.8	4.5	6.9	8	7.1	10.3	3	7.4	8.2	4.7	12.9
Net Profit Mgn % ⓘ	0.7	1	4.4	4.6	0.4	-0.5	-4.5	2.9	2.9	2.7	2.3
Debt to Equity ⓘ	0.3	0.3	0.2	0.4	0.7	0.7	0.7	0.6	0.6	0.4	0
Working Cap Days ⓘ	170	215	185	195	186	232	266	146	151	176	66
Cash Conv. Cycle ⓘ	104	149	114	95	72	93	114	58	76	112	21

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	13.11	10.99	15.14	12.96	12.82	14.09	14.60	26.87	26.73	21.15
Operating Expenses ⓘ +	12.61	10.50	14.10	11.94	11.91	12.64	14.17	24.88	24.53	20.15
Manufacturing Costs	8.91	7.07	9.44	7.49	7.82	8.77	9.88	17.06	16.57	14
Material Costs	1.51	1.15	1.69	1.44	0.87	0.73	0.60	1.57	1.31	0.78
Employee Cost	1.13	0.90	0.77	0.85	0.85	1.03	1.13	1.49	1.72	2
Other Costs ⓘ	1.06	1.38	2.20	2.16	2.37	2.12	2.56	4.77	4.93	3.36
Operating Profit ⓘ	0.50	0.49	1.04	1.02	0.91	1.45	0.43	1.99	2.20	1
Operating Profit Margin (%)	3.8%	4.5%	6.9%	7.9%	7.1%	10.3%	3.0%	7.4%	8.2%	4.7%
Other Income ⓘ +	0.37	0.26	0.69	0.24	0.23	0.19	0.16	0.28	0.48	1.65
Exceptional Items ⓘ	0	0	0	0	0	0.45	0	0	0	0
Interest ⓘ	0.21	0.21	0.13	0.15	0.32	0.47	0.46	0.47	0.47	0.54
Depreciation ⓘ	0.41	0.38	0.33	0.32	0.66	1.27	1.09	0.81	1.20	1.25
Profit Before Tax ⓘ	0.25	0.17	1.27	0.80	0.16	0.35	-0.95	0.98	1.01	0.87
Tax ⓘ	0.08	0.05	0.28	0.21	0.11	0.11	-0.29	0.22	0.24	0.29
Profit After Tax	0.17	0.12	0.99	0.59	0.05	0.24	-0.66	0.77	0.77	0.58
PAT Margin (%)	1.3%	1.1%	6.6%	4.6%	0.4%	1.7%	-4.5%	2.9%	2.9%	2.7%
Adjusted EPS (₹)	0.3	0.2	2.0	1.2	0.1	0.5	-1.3	1.5	1.5	1.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Beryl Drugs - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	6.66	6.79	6.67	7.53	7.63	7.93	7.29	8.07	8.92	9.50
Share Capital ⓘ	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09
Reserves ⓘ	1.57	1.70	1.57	2.43	2.53	2.84	2.20	2.97	3.83	4.41
Debt +	1.68	1.69	1.46	3.05	4.71	4.34	5.29	4.54	5.09	4.07
Long Term Debt	0	0.09	0.07	1.30	2.31	1.99	1.68	2.71	2.40	1.74
Short Term Debt	1.67	1.60	1.39	1.76	2.39	2.35	3.62	1.84	2.69	2.34
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.74	1.16	1.45	1.79	1.80	2.22	3.06	3.25	2.02	1.12
Others Liabilities ⓘ	0.82	1.43	1.22	2.12	2.78	4.16	2	1.62	1.67	1.34
Total Liabilities ⓘ	9.91	11.07	10.80	14.49	16.91	18.65	17.65	17.48	17.71	16.03
Fixed Assets
Net Fixed Assets ⓘ +	2.44	2.26	2.04	1.67	8.34	7.33	5.86	5.81	5.96	6.01
Gross Block	8.96	9.15	2.67	2.54	9.84	10.09	9.69	10.44	11.65	12.93
Accumulated Depreciation	6.52	6.89	0.62	0.87	1.50	2.76	3.83	4.63	5.68	6.92
CWIP ⓘ	0	0	0.08	6.24	0	0	0	0	0	0
Investments ⓘ	0.68	0.68	0.39	0.77	0.82	0.12	0.16	0.15	0	0
Inventories	1.54	2.69	1.35	0.76	1.16	2.27	2.98	1.05	1.26	1.90
Trade Receivables	3.53	3.60	4.83	3.44	3.45	4.54	4.45	6.90	7.58	5.46
Cash Equivalents	0.63	0.77	0.14	0.10	0.40	0.45	0.67	0.57	0.12	0.81
Others Assets ⓘ	1.07	1.08	1.97	1.52	2.74	3.94	3.53	2.99	2.77	1.86
Total Assets ⓘ	9.91	11.07	10.80	14.49	16.91	18.65	17.65	17.48	17.71	16.03

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.13	0.27	-0.10	3.35	0.18	0.34	-0.47	2.39	0.82	2.64
PBT ⓘ	0.27	0.17	1.27	0.80	0.16	0.35	-0.95	0.98	1.01	0.87
Adjustment ⓘ	0.66	0.40	-0.39	0.28	0.83	1.14	1.37	1.12	1.53	1.64
Changes in Working Capital ⓘ	-0.54	-0.13	-0.87	2.53	-0.66	-1.13	-0.85	0.35	-1.52	0.31
Tax Paid ⓘ	-0.16	-0.12	-0.11	-0.26	-0.15	-0.02	-0.03	-0.06	-0.20	-0.18
Cash Flow From Investing Activity ⓘ +	0.17	0.05	-0.03	-5.01	-1.55	0.26	0.52	-1.18	-1.08	-0.40
Capex	-0.20	-0.20	0.17	-0.06	-1.88	-0.24	0.40	-0.75	-1.33	-1.28
Net Investments	0	0	0.28	0	0	0.97	0	0	0.22	0
Others ⓘ	0.37	0.25	-0.48	-4.95	0.32	-0.48	0.13	-0.43	0.03	0.88
Cash Flow From Financing Activity ⓘ +	-0.23	-0.19	-0.36	1.62	1.67	-0.54	-0.24	-1.20	0.10	-1.55
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0.09	-0.02	1.39	1.35	-0.07	-0.31	1.03	-0.25	-0.66
Interest Paid ⓘ	-0.21	-0.20	-0.13	-0.15	-0.32	-0.47	-0.41	-0.44	-0.46	-0.53
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.02	-0.08	-0.21	0.37	0.64	-0	0.48	-1.80	0.81	-0.36
Net Cash Flow ⓘ	-0.19	0.13	-0.49	-0.04	0.30	0.06	-0.18	0.01	-0.16	0.69

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	2.54	1.74	14.8	8.35	0.63	3.09	-8.68	10	9.07	6.3
ROCE (%)	5.55	4.48	16.88	9.96	4.05	6.28	-3.82	11.51	11.14	10.15
Asset Turnover Ratio	1.32	1.09	1.4	1.02	0.82	0.79	0.8	1.53	1.52	1.25
PAT to CFO Conversion(x)	-0.76	2.25	-0.1	5.68	3.6	1.42	N/A	3.1	1.06	4.55
Working Capital Days
Receivable Days	96.80	113.70	100.50	116.40	98.10	103.50	112.30	77.10	98.90	112.60
Inventory Days	40.80	67.50	48.20	29.70	27.40	44.40	65.60	27.40	15.80	27.30
Payable Days	286.50	301.80	282	410.30	754.80	1,005.90	1,616.70	735.10	733.90	729.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Beryl Drugs Ltd FAQs

The current trading price of Beryl Drugs on 07-Jul-2026 16:59 is ₹22.76.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Jul-2026 the market cap of Beryl Drugs stood at ₹10.51 Cr

The latest P/E ratio of Beryl Drugs as of 06-Jul-2026 is 24.74.

The latest P/B ratio of Beryl Drugs as of 06-Jul-2026 is 1.07.

The 52-week high of Beryl Drugs is ₹30.00 and the 52-week low is ₹15.92.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beryl Drugs is ₹18.82 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Beryl Drugs Ltd is a below average quality company.

The key valuation ratios of Beryl Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beryl Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Beryl Drugs Ltd

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products.

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

Small volume injectables in liquid form
Small volume injectables in dry powder form
Variety of eye and ear drops
I.V.Fluids in polypack and glass bottles
Variety of vetrinary medicines

Award/recognition

The company has received ISO 9001:2000 certification for its quality management.

You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Beryl Drugs Ltd (524606)

Beryl Drugs Ltd (524606)

Beryl Drugs stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Beryl Drugs - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Beryl Drugs Ltd FAQs

About Beryl Drugs Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Beryl Drugs Ltd (524606)

Beryl Drugs Ltd (524606)

Beryl Drugs stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Beryl Drugs - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Beryl Drugs Ltd FAQs

What is the share price of Beryl Drugs?

What is the market cap of Beryl Drugs?

What is the P/E ratio of Beryl Drugs?

What is the P/B ratio of Beryl Drugs?

What is the 52-week high and low of Beryl Drugs?

What is the TTM revenue of Beryl Drugs?

Is Beryl Drugs Ltd a good quality company?

Is Beryl Drugs Ltd undervalued or overvalued?

Is Beryl Drugs Ltd a good buy now?

About Beryl Drugs Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.